Zevra Therapeutics, Inc. - Common Stock (ZVRA)

Data from Stocktwits indicated that retail sentiment on SPY and QQQ was stabilizing.

Oil whipsawed, with WTI briefly topping $119 before plunging toward the low $80s as Trump said the Iran war could end soon.

For the fourth quarter, Zevra announced net revenue of $34.1 million, exceeding an analyst estimate of $28.05 million.

Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Zevra Therapeutics, Inc. (NASDAQ: ZVRA). The investigation focuses on Zevra’s executive officers and whether investor losses may be recovered under federal securities laws.

When a biotech rallies nearly 200% and still gets trimmed, the real story likely isn’t about fear or a loss of conviction.

ANI is firing on all cylinders operationally, which makes this exit less about fundamentals and more about portfolio discipline at a moment when expectations might be sky-high.

Zevra (ZVRA) Q3 2025 Earnings Call Transcript

Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday.

Zevra Therapeutics (NASDAQ: ZVRA) has captured significant attention in the financial markets with its recent robust stock performance and a compelling "Strong" Relative Strength Rating. As of early October 2025, the biopharmaceutical company, focused on rare diseases, is demonstrating a positive trajectory, fueled by critical regulatory milestones, impressive financial results,

Shares of PepGen Inc. (NASDAQ: PEPG) rose sharply in pre-market trading after the company announced the launch of an underwritten public offering of common stock and pre-funded warrants.

Zevra Therapeutics (NASDAQGS: ZVRA), a commercial-stage company focused on therapies for rare diseases, announced that four posters on MIPLYFFA (arimoclomol) will be presented at the International Congress of Inborn Errors of Metabolism (ICIEM), held Sept. 2-6, 2025, in Kyoto, Japan. MIPLYFFA, approved in the U.S. for the treatment of Niemann-Pick disease type C (NPC), will be highlighted in a Best Poster award-winning presentation (#BP-19) detailing its unique mechanism of action targeting NPC pathophysiology. Additional presentations will feature positive new data from a pediatric substudy in patients younger than two years old and a prespecified efficacy analysis in patients on miglustat who switched from placebo to MIPLYFFA.

Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.

Zevra Therapeutics stock gapped down Wednesday after its first-ever quarterly profit missed even more bullish expectations.

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.